Foralumab

Tiziana Life Sciences announces positive results for nasal anti-CD3 antibody (foralumab) combined with semaglutide, showing improved liver homeostasis and reduced inflammation in diet-induced obesity models.

Tiziana Life Sciences reports promising progress in neurodegenerative and autoimmune disease treatments, particularly with Foralumab, which shows potential for more effective and less harmful therapies for conditions like multiple sclerosis. A Phase 2 study is underway, and the FDA has granted Fast Track designation.

The 'Multiple Sclerosis - Pipeline Insight, 2024' report by ResearchAndMarkets.com covers 80+ companies and 85+ pipeline drugs, including IMU-838 (Immunic), Masitinib (AB Science), Foralumab (Tiziana Life Sciences), IMCY-0141 (ImCyse), and BMS-986353 (Bristol-Myers Squibb). It provides insights into clinical and nonclinical stage products, therapeutics assessment, and pipeline development activities.

Tiziana Life Sciences receives $4 million NIH grant for intranasal anti-CD3 research in Alzheimer’s disease, aiming to modulate immune activity and slow progression. The grant supports preclinical and clinical studies, with plans to initiate first-in-human trials in the coming months. Foralumab, a fully human anti-CD3 monoclonal antibody, has shown potential in treating neurodegenerative conditions.